A Phase 2 interventional study of Fingolimod in Multiple Sclerosis, sponsored by Novartis. Completed at 20 sites in Japan. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2013-09-04.
Sponsored by Novartis · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.
Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 20th largest by enrollment, is one of 3 that started in 2008, is one of 4 in phase 2, and was the 7th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.
Browse Multiple Sclerosis studies →2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in United States, Poland, Slovakia
Ages 10–17
Biogen
Ages 10–17
By country, each count listing its studies:
fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 13 · Phase 4 17
First in 2003; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 143 is above the median of 50 across 2,205 interventional studies indexed under Multiple Sclerosis.
Median enrollment 167 across the 34 interventional studies. Of the 28 that completed or were terminated, 23 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 6 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
106 studies in Multiple Sclerosis by Novartis: 9 open now, 24 under way, 6 of them phase 3. Of 78 finished, 45 (58%) have results posted.
Among the 106 studies in Multiple Sclerosis by Novartis, this one is the 33rd largest by enrollment of the 64 interventional ones that give a count, is one of 3 that started in 2008, is one of 12 in phase 2, and was the 7th registered.
Novartis’s Multiple Sclerosis studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing fingolimod in Multiple Sclerosis, from their registry updates:
Among Novartis’s 106 in Multiple Sclerosis:
This tab as a report to print or save as PDF → With an account.
This study was an extension study of NCT00537082. This study was designed to evaluate the efficacy and safety of long-term administration of 0.5 mg or 1.25 mg of fingolimod (FTY720) to relapsing multiple sclerosis.
A decision was made to switch all patients on fingolimod 1.25 mg/day to fingolimod 0.5 mg/day in an amendment to the study protocol. The study became open-label with all patients receiving fingolimod 0.5 mg/day on 22 Feb 2010.
The efficacy data for Months 0-6 in this study report is from the core study NCT00537082.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria applied to the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who received fingolimod 0.5 orally once daily in the core study continued on the same dose in this extension study.
Drug: Fingolimod
Patients who received fingolimod 1.25 mg orally once daily in the core study continued on the same dose in this extension study.
Drug: Fingolimod
Patients who were randomized to placebo in the core study were re-randomized to either fingolimod 0.5 or 1.25 mg (1:1) orally once daily in this extension study.
Drug: Fingolimod
Fingolimod was supplied in capsules.
Also known as: Gilenya, Imsera
Percentage of Patients Free of Gd-enhanced T1 Weighted Magnetic Resonance Imaging (MRI) Lesions
To ensure consistency, MRI scans were evaluated centrally at the Institute of Neurotherapeutics in Kyoto, Japan. After checking the scans for completeness and quality, all scans were analyzed by blinded readers (experienced neurologists). The number of Gd-enhanced T1 weighted MRI lesions were counted and recorded. Lesions expanding through several slices were counted as only 1 lesion.
Time frame: Months 6, 9, 12, 18, 24, 36, and 48
Percentage of Patients Free of New or Newly Enlarged T2 Weighted MRI Lesions
To ensure consistency, MRI scans were evaluated centrally at the Institute of Neurotherapeutics in Kyoto, Japan. After checking the scans for completeness and quality, all scans were analyzed by blinded readers (experienced neurologists). The number of new or newly enlarged T2 weighted MRI lesions were counted and recorded. New lesions were identified by comparing each lesion with previous scans. Lesions expanding through several slices were counted as only 1 lesion.
Time frame: Months 0-3, 3-6, 6-9, 9-12, 12-18, 18-24, 24-36,36-48, and 48 to the end of the study (up to 4 years)
Aggregate Annualized Relapse Rate (ARR) Based on Confirmed Relapses
The ARR was defined as the total number of relapses for all patients in the treatment arm / total number of days in the study for all patients in the treatment arm for the specific period of time × 365.25. General definition of relapse: Appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from the onset of a preceding clinical demyelinating event. The abnormality must be present for at least 24 hours and occur in the absence of fever (\< 37.5°C) or infection. A relapse was to be confirmed by a neurologist trained on the Expanded Disability Status Scale (EDSS). A relapse must be accompanied by an increase of at least half a step (0.5) on the EDSS or an increase of 1 point on 2 different Functional Systems (FS) of the EDSS or 2 points on 1 of the FS (excluding Bowel/Bladder or Cerebral FS).
Time frame: Months 0-6, 6-12, 12-24, 24-36, 36-48, and 48 to the end of the study (up to 4 years)
Percentage of Patients Relapse-free at the End of the Study
Patients who did not experience any relapses confirmed by a neurologist during the study were regarded as relapse-free patients.
Time frame: Baseline to the end of the study (up to 4 years)
Percentage of Patients Free From 3-month and 6-month Confirmed Disability Progression at Their Last Expanded Disability Status Scale (EDSS) Assessment
Disability progression was measured by the EDSS score. A trained neurologist grades the multiple sclerosis (MS) disability of the patient on a scale of 0-5 (no to severe disability) in 8 Functional Systems (FS): Pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, cerebral (or mental), and other. The EDSS score ranges from 0-10 (normal to dead) with higher scores indicating greater disability. A 3-month confirmed disability progression was defined as a 3-month sustained increase from baseline in the EDSS score, that is, every EDSS score obtained (scheduled or unscheduled) within 3-months after the first progression met the following progression criteria: One point (1) increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point (0.5) increase in patients with baseline EDSS score of 5.5 or above. A 6-month confirmed disability progression was defined exactly the same except that the sustained progression had to last 6 months.
Time frame: Baseline to the end of the study (up to 4 years)
Change From Core Study Baseline in the Expanded Disability Status Scale (EDSS) Score
Disability progression was measured by the EDSS score. A trained neurologist grades the multiple sclerosis (MS) disability of the patient on a scale of 0-5 (no to severe disability) in 8 Functional Systems (FS): Pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, cerebral (or mental), and other. The EDSS score ranges from 0-10 (normal to dead) with higher scores indicating greater disability. A 3-month confirmed disability progression was defined as a 3-month sustained increase from baseline in the EDSS score, that is, every EDSS score obtained (scheduled or unscheduled) within 3-months after the first progression met the following progression criteria: One point (1) increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point (0.5) increase in patients with baseline EDSS score of 5.5 or above. A 6-month confirmed disability progression was defined exactly the same except that the sustained progression had to last 6 months.
Time frame: Baseline to Months 12, 24, 36, 48, and end of study (up to 4 years)
| Milestone | Fingolimod 0.5 mg | Fingolimod 1.25 mg | Placebo-fingolimod 0.5 mg | Placebo-fingolimod 1.25 mg |
|---|---|---|---|---|
| Started | 47 | 46 | 27 | 23 |
| Switched to 0.5mg (open label) | 45 | 41 | 23 | 17 |
| Completed | 38 | 36 | 18 | 15 |
| Not completed | 9 | 10 | 9 | 8 |
| Withdrew: Adverse event | 6 | 2 | 8 | 5 |
| Withdrew: Protocol deviation | 1 | 2 | 0 | 1 |
| Withdrew: Administrative problems | 0 | 2 | 0 | 1 |
| Withdrew: Subject withdrew consent | 0 | 2 | 0 | 1 |
| Withdrew: Unsatisfactory therapeutic effect | 2 | 0 | 1 | 0 |
| Withdrew: Abnormal laboratory value(s) | 0 | 2 | 0 | 0 |
To ensure consistency, MRI scans were evaluated centrally at the Institute of Neurotherapeutics in Kyoto, Japan. After checking the scans for completeness and quality, all scans were analyzed by blinded readers (experienced neurologists). The number of Gd-enhanced T1 weighted MRI lesions were counted and recorded. Lesions expanding through several slices were counted as only 1 lesion.
| Percentage of patients | Fingolimod 0.5 mg | Fingolimod 1.25 mg | Placebo-fingolimod |
|---|---|---|---|
| Month 6 (N=44, 48, 50) | 88.6 | 97.9 | 58.0 |
| Month 9 (N=44, 39, 41) | 90.9 | 94.9 | 92.7 |
| Month 12 (N=44, 42, 36) | 97.7 | 97.6 | 88.9 |
| Month 18 (N=42, 40, 37) | 92.9 | 92.5 | 94.6 |
| Month 24 (N=38, 39, 33) | 94.7 | 94.9 | 90.9 |
| Month 36 (N=25, 21, 22) | 92.0 | 85.7 | 90.9 |
| Month 48 (N=3, 4, 1) | 100.0 | 75.0 | 100.0 |
To ensure consistency, MRI scans were evaluated centrally at the Institute of Neurotherapeutics in Kyoto, Japan. After checking the scans for completeness and quality, all scans were analyzed by blinded readers (experienced neurologists). The number of new or newly enlarged T2 weighted MRI lesions were counted and recorded. New lesions were identified by comparing each lesion with previous scans. Lesions expanding through several slices were counted as only 1 lesion.
| Percentage of patients | Fingolimod 0.5 mg | Fingolimod 1.25 mg | Placebo-fingolimod |
|---|---|---|---|
| Month 0 to 3 (N=49, 50, 51) | 69.4 | 60.0 | 45.1 |
| Month 3 to 6 (N=43, 47, 48) | 86.0 | 91.5 | 43.8 |
| Month 6 to 9 (N=44, 39, 40) | 88.6 | 92.3 | 70.0 |
| Month 9 to 12 (N=44, 42, 35) | 93.2 | 95.2 | 85.7 |
| Month 12 to 18 (N=43, 40, 37) | 88.4 | 90.0 | 91.9 |
| Month 18 to 24 (N=39, 39, 33) | 94.9 | 92.3 | 87.9 |
| Month 24 to 36 (N=25, 21, 22) | 92.0 | 90.5 | 90.9 |
| Month 36 to 48 (N=3, 4, 1) | 100.0 | 100.0 | 100.0 |
| Month 48 to end of study (N=3, 3, 1) | 100.0 | 100.0 | 100.0 |
The ARR was defined as the total number of relapses for all patients in the treatment arm / total number of days in the study for all patients in the treatment arm for the specific period of time × 365.25. General definition of relapse: Appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from the onset of a preceding clinical demyelinating event. The abnormality must be present for at least 24 hours and occur in the absence of fever (\< 37.5°C) or infection. A relapse was to be confirmed by a neurologist trained on the Expanded Disability Status Scale (EDSS). A relapse must be accompanied by an increase of at least half a step (0.5) on the EDSS or an increase of 1 point on 2 different Functional Systems (FS) of the EDSS or 2 points on 1 of the FS (excluding Bowel/Bladder or Cerebral FS).
| Relapses per year | Fingolimod 0.5 mg | Fingolimod 1.25 mg | Placebo-fingolimod |
|---|---|---|---|
| Month 0 to 6 (N=57, 54, 57) | 0.539 | 0.404 | 1.131 |
| Month 6 to 12 (N=47, 46, 50) | 0.227 | 0.284 | 0.232 |
| Month 12 to 24 (N=44, 43, 39) | 0.166 | 0.223 | 0.222 |
| Month 24 to 36 (N=41, 40, 34) | 0.191 | 0.058 | 0.162 |
| Month 36 to 48 (N=28, 23, 23) | 0.164 | 0.075 | 0.309 |
| Month 48 to end of study (N=8, 6, 3) | 0.000 | 0.000 | 0.000 |
Patients who did not experience any relapses confirmed by a neurologist during the study were regarded as relapse-free patients.
| Percentage of patients | Fingolimod 0.5 mg | Fingolimod 1.25 mg | Placebo-fingolimod |
|---|---|---|---|
| Percentage of Patients Relapse-free at the End of the Study | 45.2 (26.87 to 61.95) | 62.1 (46.63 to 74.26) | 48.3 (33.29 to 61.77) |
Disability progression was measured by the EDSS score. A trained neurologist grades the multiple sclerosis (MS) disability of the patient on a scale of 0-5 (no to severe disability) in 8 Functional Systems (FS): Pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, cerebral (or mental), and other. The EDSS score ranges from 0-10 (normal to dead) with higher scores indicating greater disability. A 3-month confirmed disability progression was defined as a 3-month sustained increase from baseline in the EDSS score, that is, every EDSS score obtained (scheduled or unscheduled) within 3-months after the first progression met the following progression criteria: One point (1) increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point (0.5) increase in patients with baseline EDSS score of 5.5 or above. A 6-month confirmed disability progression was defined exactly the same except that the sustained progression had to last 6 months.
| Percentage of patients | Fingolimod 0.5 mg | Fingolimod 1.25 mg | Placebo-fingolimod |
|---|---|---|---|
| Free from 3-month confirmed disability progression | 74.3 (55.04 to 86.31) | 82.4 (67.73 to 90.87) | 90.6 (78.63 to 95.99) |
| Free from 6-month confirmed disability progression | 87.1 (73.40 to 94.03) | 90.7 (76.94 to 96.44) | 92.3 (80.51 to 97.06) |
Disability progression was measured by the EDSS score. A trained neurologist grades the multiple sclerosis (MS) disability of the patient on a scale of 0-5 (no to severe disability) in 8 Functional Systems (FS): Pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, cerebral (or mental), and other. The EDSS score ranges from 0-10 (normal to dead) with higher scores indicating greater disability. A 3-month confirmed disability progression was defined as a 3-month sustained increase from baseline in the EDSS score, that is, every EDSS score obtained (scheduled or unscheduled) within 3-months after the first progression met the following progression criteria: One point (1) increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point (0.5) increase in patients with baseline EDSS score of 5.5 or above. A 6-month confirmed disability progression was defined exactly the same except that the sustained progression had to last 6 months.
| Units on a scale | Fingolimod 0.5 mg | Fingolimod 1.25 mg | Placebo-fingolimod |
|---|---|---|---|
| Month 12 (N=45, 43, 40) | -0.02 ± 0.464 | -0.02 ± 0.831 | -0.23 ± 0.800 |
| Month 24 (N=42, 40, 35) | -0.12 ± 0.723 | -0.06 ± 1.033 | -0.21 ± 0.789 |
| Month 36 (N=25, 21, 23) | 0.16 ± 1.441 | -0.07 ± 0.912 | -0.37 ± 0.678 |
| Month 48 (N=3, 4, 1) | 1.17 ± 0.764 | -0.63 ± 0.946 | 0.00 ± 0.000 |
| End of study (N=37, 36, 32) | 0.00 ± 1.225 | -0.17 ± 0.902 | -0.31 ± 0.830 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fingolimod 1.25 mg | — | 5/46 (10.9%) | 43/46 (93.5%) |
| Fingolimod 0.5 mg | — | 8/47 (17%) | 42/47 (89.4%) |
| Placebo-fingolimod 1.25 mg | — | 5/23 (21.7%) | 21/23 (91.3%) |
| Placebo-fingolimod 0.5 mg | — | 1/27 (3.7%) | 25/27 (92.6%) |
| Event | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo-fingolimod 1.25 mg | Placebo-fingolimod 0.5 mg |
|---|---|---|---|---|
| BradycardiaCardiac disorders | 0/46 | 0/47 | 2/23 | 0/27 |
| LeukoencephalopathyNervous system disorders | 0/46 | 0/47 | 1/23 | 0/27 |
| RadiculitisNervous system disorders | 0/46 | 0/47 | 1/23 | 0/27 |
| Abortion inducedSurgical and medical procedures | 1/46 | 0/47 | 1/23 | 0/27 |
| Neuromyelitis opticaNervous system disorders | 0/46 | 0/47 | 0/23 | 1/27 |
| CataractEye disorders | 1/46 | 0/47 | 0/23 | 0/27 |
| Tooth impactedGastrointestinal disorders | 1/46 | 0/47 | 0/23 | 0/27 |
| AppendicitisInfections and infestations | 1/46 | 0/47 | 0/23 | 0/27 |
| Urinary tract infectionInfections and infestations | 1/46 | 0/47 | 0/23 | 0/27 |
| Eyeball ruptureInjury, poisoning and procedural complications | 1/46 | 0/47 | 0/23 | 0/27 |
| Event | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo-fingolimod 1.25 mg | Placebo-fingolimod 0.5 mg |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 28/46 | 29/47 | 12/23 | 15/27 |
| Liver function test abnormalInvestigations | 8/46 | 6/47 | 9/23 | 7/27 |
| LymphopeniaBlood and lymphatic system disorders | 8/46 | 6/47 | 3/23 | 2/27 |
| RashSkin and subcutaneous tissue disorders | 0/46 | 1/47 | 4/23 | 3/27 |
| HeadacheNervous system disorders | 3/46 | 8/47 | 3/23 | 1/27 |
| CystitisInfections and infestations | 7/46 | 3/47 | 1/23 | 2/27 |
| LeukopeniaBlood and lymphatic system disorders | 5/46 | 2/47 | 1/23 | 4/27 |
| StomatitisGastrointestinal disorders | 6/46 | 4/47 | 1/23 | 4/27 |
| Atrioventricular block second degreeCardiac disorders | 0/46 | 0/47 | 3/23 | 0/27 |
| DiarrhoeaGastrointestinal disorders | 6/46 | 3/47 | 2/23 | 1/27 |
| Age Continuous(years) | Fingolimod 0.5 mg | Fingolimod 1.25 mg | Placebo-fingolimod 0.5 mg | Placebo-fingolimod 1.25 mg | Total |
|---|---|---|---|---|---|
| Mean | 34.9 ± 8.95 | 35.7 ± 8.81 | 34.2 ± 9.08 | 35.5 ± 8.44 | 35.1 ± 8.78 |
| Sex: Female, Male(Participants) | Fingolimod 0.5 mg | Fingolimod 1.25 mg | Placebo-fingolimod 0.5 mg | Placebo-fingolimod 1.25 mg | Total |
|---|---|---|---|---|---|
| Female | 33 | 31 | 19 | 14 | 97 |
| Male | 14 | 15 | 8 | 9 | 46 |
The record gives a start of Apr 2008, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2013, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fingolimod